AIM: To see the effect of 3 consecutive doses of intravitreal Ranibizumab(0.5 mg) at 1 month interval under topical anaesthesia in idiopathic choroidal neovascular membrane. METHODOLOGY: 10 patients with idiopathic choroidal neovascular membrane(CNVM) were taken into our study from march 2016 to february 2019 and after proper history taking and detailed systemic and ophthalmological examinations including best corrected visual acuity(BCVA) and central macular thickness(CMT) measurement by spectral domain OCT we had injected Ranibizumab(0.5 mg) intravitreally under topical anaesthesia for 3 consecutive months and BCVA and CMT were measured at 3 months, 6 months, 9 months, 12 months after 1st dose of injection respectively. Then paired T test was applied with the help of SPSS software. CONCLUSION: Intravitreal Ranibizumab can be a safe and effective tool to handle idiopathic CNVM but long term prospective trials are mandatory to draw the conclusion.